Multiple Sclerosis*

Date/Time: Wednesday, October 7, 2020 - 3:30 PM – 5:30 PM
Track: Special Interest Group
Log in to Add to My Schedule


With a growing number of FDA-approved therapies that reduce multiple sclerosis (MS) inflammatory activity, much active research in the field is focused on identifying means of promoting remyelination, neuroprotection, and neurorepair. This SIG will focus on animal data surrounding remyelination, outcome measures that may be useful for human trials of neuroprotection/repair agents, and provide an update on a promising candidate therapy for remyelination.


  • To describe remyelination in animal models of MS.

  • To describe imaging outcome measures for trials of remyelination, neuroprotection, or neurorepair in MS.

  • To describe a candidate remyelination therapy in MS.


Brain Functional Connectivity is Related to Leptomeningeal Enhancement in Relapsing-Remitting Multiple Sclerosis: A 7-T MRI Study

CNM-Au8: Nanocatalytic Therapy for the Treatment of Chronic Optic Neuropathy

Neuroimaging Outcomes for Neuroprotection in MS: A Focus on the Retina

Progressive Multifocal Leukoencephalopathy brain and lesion segmentation from MRI: lessons learnt from deep learning

Remyelination Alters the Pattern of Myelin in the Cerebral Cortex

Vascular Comorbidity is Associated with Lower Brain Volumes in a Large Multiple Sclerosis Cohort